Cardioxipin® solution for intravenous and intramuscular administration 30 mg/ml

Cardioxipin® solution for intravenous and intramuscular administration 30 mg/ml

International nonproprietary name

Methylethylpyridinol

Pharmacological group

Антиоксидантные средства

Composition

methyl ethylpyridinol hydrochloride (emoxypine) 30 g;
disodium hydrogen phosphate dihydrate (sodium dihydrogenphosphate dodecahydrate) - 7.0 g,
sodium sulfite - 1.0 g,
water for injection - up to 1 liter.

Pharmacological action

Cardioxipin reduces permeability of the vascular wall, viscosity and coagulability of blood, ability of erythrocytes to glue. Reinforces the fibrinolysis process. Improves microcirculation. Inhibits effectively free radical oxidation of lipids of biomembranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has an antitoxic effect. In extreme situations associated with increased lipid peroxidation and hypoxia, the drug optimizes bioenergetic processes. The drug protects the retina from damaging effect of high-intensity light, increases resorption of intraocular hemorrhages.
Cardioxipin reduces the signs of cerebral hemodysfunction.
The drug increases brain resistance to hypoxia and ischemia. In case of cerebral circulation diorders (ischemic and hemorrhagic) allows correcting vegetative dysfunctions, facilitates recovery of integrative activity of the brain, improves mnestic functions. The drug has hypolipidemic action, reduces the synthesis of triglycerides.
The drug has a pronounced cardioprotective effect.
The drug expands coronary vessels, reduces ischemic damage to the myocardium. In case of myocardial infarction the drug limits the area of the necrosis area, accelerates reparative processes, normalizes the myocardial metabolism.
The drug has beneficial effect on the clinical symptomes of myocardial infarction, reducing frequency of acute heart failure.
Promotes regulation of the oxidation and reduction system in case of circulatory failure. The drug is effective under the conditions associated with increased lipid peroxidation (including skin diseases, glaucoma, etc.).

Pharmacokinetics

After intravenous administration at dose 10 mg/ml, low half-time T1/2 - 18 min was noted, which indicates high rate of elimination of the drug from the blood. The elimination constant value is 0.041 min; total clearance is CI-214.8 ml/min, apparent volume of distribution V is -5,2 l. The drug penetrates quickly into the organs and tissues, where it is deposited and metabolized.
Five metabolites of сardioxipin, represented by dealkylated and conjugated products of its transformation were detected. Metabolites of cardioxipin are excreted by the kidneys. 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver in significant quantities.

Indications for Use

In neurology and neurosurgery: hemorrhagic stroke during the the recovery period, ischemic stroke, transient disorders of cerebral circulation, chronic cerebral circulatory dyficiency, craniocerebral trauma associated with brain contusions; postsurgical period in patients with craniocerebral trauma, operated for epi-, subdural and intracerebral hematomas, associated with brain contusions.
In cardiology: acute myocardial infarction, prevention of reperfusion syndrome, unstable angina.

Contraindications

Administration of the drug is contraindicated in case of individual intolerance, pregnancy.
During lactation the drug is not recommended to be administered due to the lack of significant safety data.
Due to the lack of safety data the drug is not recommended to be administered in children under 18 years old.

Cautions

Treatment with сardioxipin by intravenous administration method shall be conducted with monitoring blood pressure and functional state of the coagulating and anticoagulating blood systems.

Dosing and Administration

In neurology, neurosurgery and cardiology the drug administration shall be started from intravenous drip infusion (20-40 drops per minute) of 20-30 ml of 3% emoxipin solution (600-900 mg) in 200 ml of isotonic saline solution or 5% glucose solution 1-3 times per day during 5-15 days based on the disease progression, followed by transition to intramuscular injection of 2-10 ml of 3% solution 2-3 times per day during 10-30 days.

Side effect

After intravenous administration - burning sense along the vein, increased blood pressure, excitation or somnolency.
In case of predisposition to allergic reactions in rare cases itching and redness of the skin are observed.

Interaction with other medicines

α-tocopherol acetate potentiates the antioxidant effect of сardioxipin.
Сardioxipin shall not be mixed with other injection drugs in one syringe.

Form release

Storage conditions

In a dark place at temperature maximum 25 °С.

Expiration date

2 years